Welcome to MolDiag-PaCa
1. Huber, M., Bahr, I., Krätzschmar, J. R., Becker, A., Müller, E.-C., Donner, P., Pohlenz, H.-D., Schneider, M. R., Sommer, A. 2004: Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol Cell Proteomics 4, 43-55.

2. Sommer, A., Hoffmann, J., Lichtner, R. B., Schneider, M. R., Parczyk, K. 2003: Studies on the development of resistance to the pure antiestrogen FaslodexTM in three human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 85, 33-47.

3. Egner U., Krätzschmar J., Kreft B., Pohlenz H.-D.-, Schneider M. 2005: The target discovery process. Chembiochem. 6, 468-479.

4. Becker, M., Sommer, A., Krätzschmar, J. R., Seidel, H., Pohlenz, H.-D., Fichtner, I. 2005: Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen resistant subline MaCa 3366/TAM. Mol Cancer Ther. 4, 151-168.

5. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L. 1999: A high-affinity human antibody that targets tumoral blood vessels. Blood. 94, 192-198.